{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:59:19Z","timestamp":1779292759721,"version":"3.51.4"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002411","name":"Universidad ICESI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Idiopathic inflammatory myopathies (IIMs) are chronic, autoimmune diseases with several forms of presentation. Diagnosis is mostly clinical in our region. Our aim was to evaluate the autoantibody profile of patients with IIMs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study is a cross-sectional study with a prospective recollection of data, conducted between 2019\u20132021, in a single center in Cali, Colombia. Patients with a clinical diagnosis or suspicion of IIM were included. The presence of myositis-specific\/associated antibodies was evaluated by immunoblotting in serum samples. Phenotypic characterization was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 36 patients were included. The mean age was 50.6 (16.7) years, and 20 (55.6%) were female. Eighteen (50%) patients were seropositive, of which 11 (30.5%) presented one positive antibody, with anti-TIF1\u0263being the most frequent (<jats:italic>n<\/jats:italic> = 4, 11.1%), followed by anti-Ro52 (<jats:italic>n<\/jats:italic> = 2, 5.6%). Seven patients (19.4%) showed &amp;gt;1 positive antibody. Dermatomyositis was the most frequent type of IIM in seropositive patients (<jats:italic>n<\/jats:italic> = 8, 44.4%), followed by anti-synthetase syndrome (<jats:italic>n<\/jats:italic> = 4, 22.2%). Weakness was symmetric and presented in the upper and lower extremities in 11 (61.1%) patients each. Both respiratory insufficiency and weight loss were seen in 7 (38.9%) patients, Gottron papules in six (33.3%) patients, and heliotrope rash, esophageal dysmotility, and myalgia in 5 (27.8%) patients. Pulmonary interstitial disease was seen in 4 (22.2%, with antibodies for anti-Ro52, anti-MDA5 + anti-Jo1 + anti-TIF1\u0263, anti-MDA5 + anti-SAE1 + anti-NXP2, and anti-cN1A + anti-Ro52) patients, and malignancy was seen in 2 (11.1%) patients (1 with anti-Mi2\u03b2 and 1 with anti-TIF1\u0263 + anti-Mi2\u03b1). In all, 7 (19.4%) patients required intensive care (2 seropositive, 1 with anti-PL7, 1 with anti-MDA5 + anti-Jo1 + anti-TIF1\u0263), and 1 (2.8%) (seronegative) patient died.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study is the first study in the Southwest of Colombia that evaluates myositis-specific\/associated antibodies in IIM. Half of the patients were seropositive. Anti-TIF1\u0263was the most frequent MSA and anti-Ro52 was the most frequent MAA. Several patients presented antibody combinations. Further studies are needed to fully associate phenotypes with antibodies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.954937","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T04:33:57Z","timestamp":1660538037000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Profile of specific and associated autoantibodies in patients with idiopathic inflammatory myopathies in a Colombian population"],"prefix":"10.3389","volume":"9","author":[{"given":"Andr\u00e9s","family":"Hormaza-Jaramillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Bedoya-Joaqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Germ\u00e1n","family":"Puerta-Sarmiento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lady J.","family":"Rios-Serna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Delgado-Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Nieto-Aristiz\u00e1bal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Ruiz-Ordo\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/s0950-3579(05)80255-9","article-title":"Inflammatory myopathies.","volume":"9","author":"Oddis","year":"1995","journal-title":"Baillieres Clin Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1126\/science.158.3807.1453","article-title":"Myxovirus-like structures in a case of human chronic polymyositis.","volume":"158","author":"Chou","year":"1967","journal-title":"Science."},{"key":"B3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis.","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies.","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers."},{"key":"B5","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/rheumatology\/kep078","article-title":"Myositis-specific autoantibodies: Their clinical and pathogenic significance in disease expression.","volume":"48","author":"Gunawardena","year":"2009","journal-title":"Rheumatology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nrneurol.2011.63","article-title":"Autoimmune myopathies: Autoantibodies, phenotypes and pathogenesis.","volume":"7","author":"Mammen","year":"2011","journal-title":"Nat Rev Neurol."},{"key":"B7","first-page":"820","article-title":"Why do patients with myositis die? A retrospective analysis of a single-centre cohort.","volume":"34","author":"Amaral Silva","year":"2016","journal-title":"Clin Exp Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","article-title":"Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease.","volume":"194","author":"Johnson","year":"2016","journal-title":"Lung."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","article-title":"The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.","volume":"51","author":"Koga","year":"2012","journal-title":"Rheumatology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: A systematic review and meta-analysis.","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort.","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun."},{"key":"B12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/acr.22728","article-title":"Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis.","volume":"68","author":"Moghadam-Kia","year":"2016","journal-title":"Arthritis Care Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00296-009-0884-9","article-title":"Characteristics of interstitial lung disease in SS-A positive\/Jo-1 positive inflammatory myopathy patients.","volume":"29","author":"V\u00e1ncsa","year":"2009","journal-title":"Rheumatol Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/08916930600623791","article-title":"In patients with antisynthetase syndrome the occurrence of anti-Ro\/SSA antibodies causes a more severe interstitial lung disease.","volume":"39","author":"La Corte","year":"2006","journal-title":"Autoimmunity."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1002\/art.30513","article-title":"Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: A series of 107 patients.","volume":"63","author":"Marie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/ar2276","article-title":"Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: Insights into clinical features and outcomes.","volume":"9","author":"Koenig","year":"2007","journal-title":"Arthritis Res Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1097\/RHU.0000000000001350","article-title":"Myositis-specific antibodies and myositis-associated antibodies in patients with idiopathic inflammatory myopathies from the PANLAR myositis study group.","volume":"27","author":"Gonz\u00e1lez-Bello","year":"2021","journal-title":"J Clin Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s13311-018-00676-2","article-title":"Autoimmune myopathies: Updates on evaluation and treatment.","volume":"15","author":"McGrath","year":"2018","journal-title":"Neurotherapeutics."},{"key":"B20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-3-642-50118-0_8","article-title":"Neuromuscular complications of primary Sj\u00f6gren\u2019s syndrome.","author":"Alexander","year":"1987","journal-title":"Sj\u00f6gren\u2019s syndrome. Clinical and immunological aspects."},{"key":"B21","first-page":"649","article-title":"Myositis in primary Sj\u00f6gren syndrome. Report of 3 cases.","volume":"21","author":"Kraus","year":"1994","journal-title":"J Rheumatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/rheumatology\/41.4.440","article-title":"Primary Sj\u00f6gren\u2019s syndrome associated with inclusion body myositis.","volume":"41","author":"Kanellopoulos","year":"2002","journal-title":"Rheumatology."},{"key":"B23","first-page":"457","article-title":"Myositis in primary Sj\u00f6gren\u2019s syndrome: Data from a multicentre cohort.","volume":"33","author":"Colafrancesco","year":"2015","journal-title":"Clin Exp Rheumatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1007\/s10067-021-05797-2","article-title":"Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: Reported by the argentine registry of inflammatory myopathies of the argentine society of rheumatology.","volume":"40","author":"G\u00f3mez","year":"2021","journal-title":"Clin Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies.","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10067-018-4267-z","article-title":"Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies.","volume":"38","author":"Zampeli","year":"2019","journal-title":"Clin Rheumatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/bjd.12564","article-title":"Meta-analysis of the association of dermatomyositis and polymyositis with cancer.","volume":"169","author":"Wang","year":"2013","journal-title":"Br J Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study.","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s12016-015-8511-x","article-title":"Idiopathic inflammatory myopathies and malignancy: A comprehensive review.","volume":"52","author":"Tiniakou","year":"2017","journal-title":"Clin Rev Allerg Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.autrev.2018.10.004","article-title":"Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays.","volume":"18","author":"Damoiseaux","year":"2019","journal-title":"Autoimmun Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients.","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun."},{"key":"B32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/ane.13331","article-title":"Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies.","volume":"143","author":"Wong","year":"2021","journal-title":"Acta Neurol Scand."},{"key":"B33","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.autrev.2017.05.003","article-title":"Integrated diagnosis project for inflammatory myopathies: An association between autoantibodies and muscle pathology.","volume":"16","author":"Suzuki","year":"2017","journal-title":"Autoimmun Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.rcreu.2020.09.008","article-title":"Clinical characterisation of patients with inflammatory myopathy in 2 tertiary care hospitals in Colombia: A descriptive survey.","volume":"28","author":"Salazar-Villa","year":"2021","journal-title":"Rev Colomb Reumatol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-013-0335-1","article-title":"Autoantibodies in polymyositis and dermatomyositis.","volume":"15","author":"Ghirardello","year":"2013","journal-title":"Curr Rheumatol Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis.","volume":"72","author":"Fiorentino","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10067-020-05274-2","article-title":"The association between myositis-specific autoantibodies and muscle pathologies in idiopathic inflammatory myopathies.","volume":"40","author":"Xu","year":"2021","journal-title":"Clin Rheumatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4078\/jrd.2019.26.3.165","article-title":"The role of autoantibodies in idiopathic inflammatory myopathies.","volume":"26","author":"Yoo","year":"2019","journal-title":"J Rheum Dis."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00331","article-title":"Clinical usefulness of autoantibodies in idiopathic inflammatory myositis.","volume":"6","author":"Garc\u00eda-De La Torre","year":"2015","journal-title":"Front Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A Comprehensive overview on myositis-specific antibodies: New and old biomarkers in idiopathic inflammatory myopathy.","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.101484","article-title":"Inflammatory muscle disease \u2013 an update.","volume":"34","author":"Baig","year":"2020","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease.","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/ar4207","article-title":"Implications in the difference of anti-Mi-2 and -p155\/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara.","volume":"15","author":"Petri","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00438","article-title":"Disease specific autoantibodies in idiopathic inflammatory myopathies.","volume":"10","author":"Stuhlm\u00fcller","year":"2019","journal-title":"Front Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: Possible association with malignancy.","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1001\/jamadermatol.2013.10416","article-title":"Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.","volume":"150","author":"Valenzuela","year":"2014","journal-title":"JAMA Dermatol."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/ar3822","article-title":"Anti-MJ\/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis\/dermatomyositis.","volume":"14","author":"Ceribelli","year":"2012","journal-title":"Arthritis Res Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.3899\/jrheum.090461","article-title":"Clinical and serologic characterization of an Argentine pediatric myositis cohort: Identification of a novel autoantibody (anti-MJ) to a 142-kDa protein.","volume":"36","author":"Espada","year":"2009","journal-title":"J Rheumatol."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08920-y","article-title":"An Italian multicenter study on Anti-NXP2 antibodies: Clinical and serological associations.","author":"Fredi","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1136\/annrheumdis-2012-201736","article-title":"Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: Comparison with a UK caucasian cohort.","volume":"72","author":"Fujimoto","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/ard.2008.097162","article-title":"Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis.","volume":"68","author":"Betteridge","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jim.2012.07.019","article-title":"Anti-SAE antibodies in autoimmune myositis: Identification by unlabelled protein immunoprecipitation in an Italian patient cohort.","volume":"384","author":"Tarricone","year":"2012","journal-title":"J Immunol Methods."},{"key":"B53","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3109\/08916934.2012.755958","article-title":"Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients.","volume":"46","author":"Muro","year":"2013","journal-title":"Autoimmunity."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1469-8","article-title":"Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: A large longitudinal cohort study.","volume":"19","author":"Yang","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2020.101503","article-title":"Clinical manifestations and treatment of antisynthetase syndrome.","volume":"34","author":"Marco","year":"2020","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1136\/ard.2006.052191","article-title":"Anti-signal recognition particle autoantibodies: Marker of a necrotising myopathy.","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s10067-020-05273-3","article-title":"Myositis-specific autoantibodies in adults with idiopathic inflammatory myopathy: Correlations with diagnosis and disease activity.","volume":"40","author":"Zhao","year":"2021","journal-title":"Clin Rheumatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3109\/14397595.2015.1091155","article-title":"Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52.","volume":"26","author":"Yamasaki","year":"2016","journal-title":"Mod Rheumatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","article-title":"Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody.","volume":"41","author":"Marie","year":"2012","journal-title":"Semin Arthritis Rheum."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.autrev.2014.08.011","article-title":"Four dermatomyositis-specific autoantibodies-anti-TIF1\u03b3, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.","volume":"13","author":"Bodoki","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B61","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1006\/jaut.1998.0265","article-title":"The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies.","volume":"12","author":"Frank","year":"1999","journal-title":"J Autoimmun."},{"key":"B62","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-019-0186-x","article-title":"Inclusion body myositis: Clinical features and pathogenesis.","volume":"15","author":"Greenberg","year":"2019","journal-title":"Nat Rev Rheumatol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: A meta-analysis revisiting the so-called antisynthetase syndrome.","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B64","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1136\/ard.60.2.116","article-title":"Autoantibody profiles in the sera of European patients with myositis.","volume":"60","author":"Brouwer","year":"2001","journal-title":"Ann Rheum Dis."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.672008","article-title":"Geographical latitude remains as an important factor for the prevalence of some myositis autoantibodies: A systematic review.","volume":"12","author":"Aguilar-Vazquez","year":"2021","journal-title":"Front Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","article-title":"Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis.","volume":"68","author":"Cruellas","year":"2013","journal-title":"Clinics (Sao Paulo)."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.954937\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T04:34:05Z","timestamp":1660538045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.954937\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":66,"alternative-id":["10.3389\/fmed.2022.954937"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.954937","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,15]]},"article-number":"954937"}}